CAR-T-cell therapy for autoimmune neurologic diseases
4 affiliations
- 1Department of Neurology, Jingmen Central Hospital
- 2Department of Neurology, Jingmen Central Hospital Affiliated to Jingchu University of Technology
- 3Department of Nursing, Jingmen Central Hospital
- 4Department of Cardiology, Jingmen Central Hospital Affiliated to Jingchu University of Technology
Abstract
Autoimmune neurologic diseases include multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, autoimmune encephalitis, myasthenia gravis, stiff-person syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and related syndromes. The contributions of B cells, plasma cells, and autoantibodies differ substantially across these disorders; however, the B-cell lineage represents a therapeutically actionable target in many of them. Chimeric antigen receptor T-cell therapy, originally developed for hematologic malignancies, offers a potential strategy for deep and potentially durable depletion of pathogenic B-lineage cells and subsequent immune reconstitution. In recent years, CD19, BCMA, dual-target, mRNA CAR-T-cell, and chimeric autoantibody receptor T-cell approaches have generated preliminary clinical or translational evidence, primarily in systemic autoimmune diseases. Clinical evidence in neurologic disorders remains limited and spans myasthenia gravis, NMOSD, MOGAD, multiple sclerosis, autoimmune encephalitis, stiff-person syndrome, and CIDP. This review summarizes the biologic rationale, disease-specific evidence, target selection, safety concerns, and trial-design considerations for CAR-T-cell therapy in autoimmune neurologic diseases. Current evidence supports further investigation of CAR-T cells in selected patients with highly refractory, antibody- or B-cell-driven neuroimmune disorders, but does not establish superiority over existing therapies. However, the field remains dominated by case reports and small early-phase studies, with randomized evidence currently confined to one phase 2b trial in myasthenia gravis. Establishing the risk-benefit profile will require stringent patient selection, disease-specific neurologic monitoring, controlled prospective studies, and long-term follow-up.
Related
- Evaluating SynthSR for MRI harmonization and quantitative analysis of hippocampal volume in autoimmune neurologic diseases
- Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Autoimmune Diseases: A Narrative Review
- Chimeric antigen receptor t-cell therapy for systemic autoimmune diseases: a systematic review
- Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases
- HDL – Immune Cell Crosstalk in Autoimmune Diseases and its Role in Accelerated Atherosclerosis
BibTeX
@article{zhao2026cartcell,
title = {{CAR-T-cell therapy for autoimmune neurologic diseases}},
author = {Yunhan Zhao and Yunyu Ding and Congfeng Tang and Zhengrong Wei and Yuqing Fan and Xianhui Hu and Jilong Yi},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1942249},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1942249/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CAR-T-cell therapy for autoimmune neurologic diseases
AU - Yunhan Zhao
AU - Yunyu Ding
AU - Congfeng Tang
AU - Zhengrong Wei
AU - Yuqing Fan
AU - Xianhui Hu
AU - Jilong Yi
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1942249
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1942249/full
AB - Autoimmune neurologic diseases include multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, autoimmune encephalitis, myasthenia gravis, stiff-person syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and related syndromes. The contributions of B cells, plasma cells, and autoantibodies differ substantially across these disorders; however, the B-cell lineage represents a therapeutically actionable target in many of them. Chimeric antigen receptor T-cell therapy, originally developed for hematologic malignancies, offers a potential strategy for deep and potentially durable depletion of pathogenic B-lineage cells and subsequent immune reconstitution. In recent years, CD19, BCMA, dual-target, mRNA CAR-T-cell, and chimeric autoantibody receptor T-cell approaches have generated preliminary clinical or translational evidence, primarily in systemic autoimmune diseases. Clinical evidence in neurologic disorders remains limited and spans myasthenia gravis, NMOSD, MOGAD, multiple sclerosis, autoimmune encephalitis, stiff-person syndrome, and CIDP. This review summarizes the biologic rationale, disease-specific evidence, target selection, safety concerns, and trial-design considerations for CAR-T-cell therapy in autoimmune neurologic diseases. Current evidence supports further investigation of CAR-T cells in selected patients with highly refractory, antibody- or B-cell-driven neuroimmune disorders, but does not establish superiority over existing therapies. However, the field remains dominated by case reports and small early-phase studies, with randomized evidence currently confined to one phase 2b trial in myasthenia gravis. Establishing the risk-benefit profile will require stringent patient selection, disease-specific neurologic monitoring, controlled prospective studies, and long-term follow-up.
SN - 1664-3224
ER -